Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | YES1 | P07947 | 1/20 | 0.68 |
| ▸ | FECH | P22830 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28342403 | 0.85 | EGFR (0.62) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL1383277 | 0.84 | EGFR (0.72) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL4862992 | 0.82 | ERBB2 (0.63) | EGFRERBB2ERBB4LCKEPHA2 | |
| SCHEMBL24087741 | 0.82 | EGFR (0.59) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL12851552 | 0.82 | EGFR (0.75) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL12205088 | 0.82 | EGFR (0.75) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL24087765 | 0.82 | ERBB2 (0.75) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL8150849 | 0.82 | EGFR (0.57) | EGFRERBB2RIPK2YES1FECH | |
| Varlitinib SCHEMBL1384037 | 0.81 | EGFR (1.00) | EGFRERBB2RIPK2YES1FECH | |
| SCHEMBL12851512 | 0.81 | EGFR (0.69) | EGFRERBB2RIPK2YES1FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379070-A1 | MALONATE SALT OF VARLITINIB | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2021-12-09 | — | — | US | disclosed |
| CN-110577520-B | Preparation method of 6-nitro-4-substituted amino quinazoline derivative | 新发药业有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-110577520-A | Preparation method of 6-nitro-4-substituted amino quinazoline derivative | 新发药业有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-7777032-B2 | N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7585975-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7501427-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ARRAY BIOPHARM, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885RIPK2 757/4885 |
| US-20210379070-A1 | MALONATE SALT OF VARLITINIB | KRAS, JAK1, JAK2 | EGFR 63/4885ERBB2 138/4885RIPK2 1308/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885RIPK2 757/4885 |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885RIPK2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.